As of February, 12 Rubius Therapeutics, Inc. (RUBY) Analysts See $-0.40 EPS

Rubius Therapeutics, Inc. (NASDAQ:RUBY)’s earnings release is awaited by WallStreet on February, 12, Zacks reports. After $-0.42 earnings per share was published last quarter, analysts now see EPS growth of -4.76 % for Rubius Therapeutics, Inc.. RUBY is reaching $15.02 during the last trading session, after decreased 2.72%.Rubius Therapeutics, Inc. has volume of 142,241 shares. Since January 11, 2018 RUBY has 0.00% and is . The stock the S&P 500 by 0.00%.

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform.The firm is valued at $1.19 billion. The firm is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.Currently it has negative earnings. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders.

For more Rubius Therapeutics, Inc. (NASDAQ:RUBY) news released briefly go to:,,, or The titles are as follows: “Sunwing helps Canadians celebrate the New Year with savings of up to 40% on vacation packages – GlobeNewswire” released on December 28, 2018, “Rubius Therapeutics Reports Third Quarter 2018 Financial Results and Operational Progress – GlobeNewswire” on November 13, 2018, “Rubius Therapeutics shares surge 35% in trading debut – MarketWatch” with a publish date: July 18, 2018, “Nasdaq Welcomes Rubius Therapeutics, Inc. (Nasdaq: RUBY) to the Nasdaq Stock Market – GlobeNewswire” and the last “Rubius Therapeutics to Announce Third Quarter 2018 Financial Results – GlobeNewswire” with publication date: November 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.